Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Healthtrust
Federal Trade Commission
Cerilliant
Teva
McKesson
Accenture
Cantor Fitzgerald

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,322,819

« Back to Dashboard

Summary for Patent: 6,322,819
Title: Oral pulsed dose drug delivery system
Abstract:A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
Inventor(s): Burnside; Beth A. (Bethesda, MD), Guo; Xiaodi (Derwood, MD), Fiske; Kimberly (Bethesda, MD), Couch; Richard A. (Chevy Chase, MD), Treacy; Donald J. (Annapolis, MD), Chang; Rong-Kun (Hockessin, DE), McGuinness; Charlotte (Bethesda, MD), Rudnic; Edward M. (North Potomac, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/176,542
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,322,819
Patent Claim Types:
see list of patent claims
Composition; Delivery;

Drugs Protected by US Patent 6,322,819

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-006 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-002 Oct 11, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,322,819

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,605,300 Oral pulsed dose drug delivery system ➤ Sign Up
RE42096 Oral pulsed dose drug delivery system ➤ Sign Up
RE41148 Oral pulsed dose drug delivery system ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Fish and Richardson
Farmers Insurance
Cipla
Healthtrust
Covington
Queensland Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.